Florida Cancer Specialists & Research Institute Earns Three-Year Accreditation for Radiation Oncology Services
23 sept. 2022 12h09 HE | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) has been awarded a three-year term of accreditation in radiation oncology,...
Aprea logo 445pt.png
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
22 sept. 2022 18h00 HE | Aprea Therapeutics
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Onconova Logo BLUE.jpg
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
22 sept. 2022 08h00 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
RevolutionLogo.png
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
22 sept. 2022 07h00 HE | Revolution Medicines, Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to...
NKGen Biotech RGB small.jpg
NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma
21 sept. 2022 13h09 HE | NKGen Biotech
SANTA ANA, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of natural killer cell...
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041
20 sept. 2022 12h47 HE | Trethera Corporation
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
1ProLynx LOGO.png
ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director
20 sept. 2022 06h00 HE | ProLynx LLC
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially...
Logo.jpg
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.
19 sept. 2022 07h45 HE | Aesther Healthcare Acquisition Corp.
NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical,...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
16 sept. 2022 16h30 HE | POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
CURE Media Group Announces 2022 Lung Cancer Heroes Award Winners
15 sept. 2022 16h11 HE | CURE Media Group
The third-annual awards program will honor three heroes for their outstanding contributions in the field of lung cancer, the deadliest and second most common form of cancer, at a Sept. 23 event during...